1887

Abstract

Equine sarcoids are highly recurrent bovine papillomavirus (BPV)-induced fibroblastic neoplasms that are the most common skin tumours in horses. In order to facilitate the study of potential equine sarcoid prophylactics or therapeutics, which can be a slow and costly process in equines, a murine model for BPV-1 protein-expressing equine sarcoid-like tumours was developed in mice through stable transfection of BPV-1 E5 and E6 in a murine fibroblast tumour cell line (K-BALB). Like equine sarcoids, these murine tumour cells (BPV-KB) were of fibroblast origin, were tumorigenic and expressed BPV-1 proteins. As an initial investigation of the preclinical potential of this tumour model for equine sarcoids prophylactics, mice were immunized with BPV-1 E5E6 Venezuelan equine encephalitis virus replicon particles, prior to BPV-KB challenge, which resulted in an increased tumour-free period compared with controls, indicating that the BPV-KB murine model may be a valuable preclinical alternative to equine clinical trials.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000212
2015-09-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/9/2764.html?itemId=/content/journal/jgv/10.1099/vir.0.000212&mimeType=html&fmt=ahah

References

  1. Aaronson S.A. , Weaver C.A. . ( 1971;). Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J Gen Virol 13: 245–252 [CrossRef] [PubMed].
    [Google Scholar]
  2. Ashrafi G.H. , Tsirimonaki E. , Marchetti B. , O'Brien P.M. , Sibbet G.J. , Andrew L. , Campo M.S. . ( 2002;). Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 21: 248–259 [CrossRef] [PubMed].
    [Google Scholar]
  3. Bogaert L. , Van Poucke M. , De Baere C. , Dewulf J. , Peelman L. , Ducatelle R. , Gasthuys F. , Martens A. . ( 2007;). Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid. J Gen Virol 88: 2155–2161 [CrossRef] [PubMed].
    [Google Scholar]
  4. Bogaert L. , Martens A. , Depoorter P. , Gasthuys F. . ( 2008a;). Equine sarcoids–part 1: clinical presentation and epidemiology. Vlaams Diergen Tijds 77: 2–9.
    [Google Scholar]
  5. Bogaert L. , Martens A. , Van Poucke M. , Ducatelle R. , De Cock H. , Dewulf J. , De Baere C. , Peelman L. , Gasthuys F. . ( 2008b;). High prevalence of bovine papillomaviral DNA in the normal skin of equine sarcoid-affected and healthy horses. Vet Microbiol 129: 58–68 [CrossRef] [PubMed].
    [Google Scholar]
  6. Campo M.S. . ( 2002;). Animal models of papillomavirus pathogenesis. Virus Res 89: 249–261 [CrossRef] [PubMed].
    [Google Scholar]
  7. Chambers G. , Ellsmore V.A. , O'Brien P.M. , Reid S.W. , Love S. , Campo M.S. , Nasir L. . ( 2003;). Association of bovine papillomavirus with the equine sarcoid. J Gen Virol 84: 1055–1062 [CrossRef] [PubMed].
    [Google Scholar]
  8. de la Luz Garcia-Hernandez M. , Gray A. , Hubby B. , Klinger O.J. , Kast W.M. . ( 2008;). Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68: 861–869 [CrossRef] [PubMed].
    [Google Scholar]
  9. Horwitz B.H. , Burkhardt A.L. , Schlegel R. , DiMaio D. . ( 1988;). 44-amino-acid E5 transforming protein of bovine papillomavirus requires a hydrophobic core and specific carboxyl-terminal amino acids. Mol Cell Biol 8: 4071–4078 [PubMed].[CrossRef]
    [Google Scholar]
  10. Klein W.R. , Bras G.E. , Misdorp W. , Steerenberg P.A. , de Jong W.H. , Tiesjema R.H. , Kersjes A.W. , Ruitenberg E.J. . ( 1986;). Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol Immunother 21: 133–140 [CrossRef] [PubMed].
    [Google Scholar]
  11. Laatikainen A. , Sarkkinen H. , Syrjänen K. , Mäntyjärvi R. . ( 1990;). Local immune reaction in syngeneic mice against tumorigenic and nontumorigenic BPV-transformed mouse cell lines. APMIS 98: 909–915 [CrossRef] [PubMed].
    [Google Scholar]
  12. Lunardi M. , de Alcântara B.K. , Otonel R.A. , Rodrigues W.B. , Alfieri A.F. , Alfieri A.A. . ( 2013;). Bovine papillomavirus type 13 DNA in equine sarcoids. J Clin Microbiol 51: 2167–2171 [CrossRef] [PubMed].
    [Google Scholar]
  13. Mäntyjärvi R.A. , Sarkkinen H. , Karajalainen H. , Parkkinen S. , Ryhänen A. , Syrjänen K. , Jägerroos H. , Nurmi T. . ( 1988;). Tumour-associated antigens in primary mouse fibroblasts induced by transformation with bovine papillomavirus type 1. Exp Pathol 35: 25–33 [CrossRef] [PubMed].
    [Google Scholar]
  14. Marchetti B. , Ashrafi G.H. , Tsirimonaki E. , O'Brien P.M. , Campo M.S. . ( 2002;). The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface. Oncogene 21: 7808–7816 [CrossRef] [PubMed].
    [Google Scholar]
  15. Marchetti B. , Gault E.A. , Cortese M.S. , Yuan Z. , Ellis S.A. , Nasir L. , Campo M.S. . ( 2009;). Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. J Gen Virol 90: 2865–2870 [CrossRef] [PubMed].
    [Google Scholar]
  16. McConaghy F.F. , Davis R.E. , Hodgson D.R. . ( 1994;). Equine sarcoid: a persistent therapeutic challenge. Compend Contin Educ Pract Vet 16: 1022–1029.
    [Google Scholar]
  17. Mohammed H.O. , Rebhun W.C. , Antczak D.F. . ( 1992;). Factors associated with the risk of developing sarcoid tumours in horses. Equine Vet J 24: 165–168 [CrossRef] [PubMed].
    [Google Scholar]
  18. Nasir L. , Campo M.S. . ( 2008;). Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet Dermatol 19: 243–254 [CrossRef] [PubMed].
    [Google Scholar]
  19. Nogueira S.A. , Torres S.M. , Malone E.D. , Diaz S.F. , Jessen C. , Gilbert S. . ( 2006;). Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study. Vet Dermatol 17: 259–265 [CrossRef] [PubMed].
    [Google Scholar]
  20. Otten N. , von Tscharner C. , Lazary S. , Antczak D.F. , Gerber H. . ( 1993;). DNA of bovine papillomavirus type 1 and 2 in equine sarcoids: PCR detection and direct sequencing. Arch Virol 132: 121–131 [CrossRef] [PubMed].
    [Google Scholar]
  21. Thomas M. , Pim D. , Banks L. . ( 2006;). The role of the HPV E6 oncoprotein in malignant progression. . In Papillomavirus Research: From Natural History to Vaccines and Beyond, pp. 115–131. Edited by Saveria Campo M. . Wymondham: Caister Academic Press;.
    [Google Scholar]
  22. Velders M.P. , McElhiney S. , Cassetti M.C. , Eiben G.L. , Higgins T. , Kovacs G.R. , Elmishad A.G. , Kast W.M. , Smith L.R. . ( 2001;). Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 61: 7861–7867 [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.000212
Loading
/content/journal/jgv/10.1099/vir.0.000212
Loading

Data & Media loading...

Supplements

Supplementary Data



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error